Malpractice Claims Following Major Liver and Pancreatic Surgeries: What Can we Learn?

被引:0
作者
Zaman, Muizz [1 ,2 ]
Li, Jian Harvard [1 ]
Dhir, Mashaal [2 ]
机构
[1] SUNY Upstate Med Univ, Norton Coll Med, 766 Irving Ave, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Dept Surg, Syracuse, NY USA
关键词
Complications; Hepatopancreaticobiliary; Liver; Medical malpractice; Pancreas; Surgical oncology; MEDICAL MALPRACTICE; CAREER SATISFACTION; CANCER; LITIGATION; ONCOLOGISTS; RESECTION; SERVICES; BURNOUT; COSTS; RISK;
D O I
10.1016/j.jss.2024.03.026
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: General surgery is a highly litigious specialty. Lawsuits can be a source of emotional distress and burnout for surgeons. Major hepatic and pancreatic surgeries are technically challenging general surgical oncology procedures associated with an increased risk of complications and mortality. It is unclear whether these operations are associated with an increased risk of lawsuits. The objective of the present study was to summarize the medical malpractice claims surrounding pancreatic and hepatic surgeries from publicly available court records. Methods: The Westlaw legal database was searched and analyzed for relevant malpractice claims from the last two decades. Results: Of 165 search results, 30 (18.2%) cases were eligible for inclusion. Appellant cases comprised 53.3% of them. Half involved a patient death. Including co-defendants, a majority (n = 21, 70%) named surgeons as defendants, whereas several claims (n = 13, 43%) also named non-surgeons. The most common cause of alleged malpractice was a delay in diagnosis (n = 12, 40%). In eight of these, surgery could not be performed. The second most common were claims alleging the follow-up surgery was due to negligence (n = 6). Collectively, 20 claims were found in favor of the defendant. Seven verdicts (23.3%) returned in favor of the plaintiff, two of which resulted in monetary awards (totaling $1,608,325 and $424,933.85). Three cases went to trial or delayed motion for summary judgment. There were no settlements. Conclusions: A defendant verdict was reached in two-thirds of malpractice cases involving major hepatic or pancreatic surgery. A delay in diagnosis was the most cited claim in hepatopancreaticobiliary lawsuits, and defendants may often practice in nonsurgical specialties. While rulings favoring plaintiffs are less frequent, the payouts may be substantial. (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页码:291 / 299
页数:9
相关论文
共 50 条
  • [21] What can we learn from DNA methylation studies in lupus?
    Ferrete-Bonastre, Anna Guiomar
    Cortes-Hernandez, Josefina
    Ballestar, Esteban
    CLINICAL IMMUNOLOGY, 2022, 234
  • [22] Epidemiology of ageing with HIV: what can we learn from cohorts?
    Sabin, Caroline A.
    Reiss, Peter
    AIDS, 2017, 31 : S121 - S128
  • [23] Afterword: What We Can Learn from Military Children and Families
    Masten, Ann S.
    FUTURE OF CHILDREN, 2013, 23 (02) : 199 - 212
  • [24] What Have We Learned From Malpractice Claims Involving the Surgical Management of Benign Biliary Disease?
    Strasberg, Steven M.
    ANNALS OF SURGERY, 2019, 269 (05) : 792 - 793
  • [25] Association between continuity of care (COC), healthcare use and costs: what can we learn from claims data? A rapid review
    Anna Nicolet
    Muaamar Al-Gobari
    Clémence Perraudin
    Joël Wagner
    Isabelle Peytremann-Bridevaux
    Joachim Marti
    BMC Health Services Research, 22
  • [26] Association between continuity of care (COC), healthcare use and costs: what can we learn from claims data? A rapid review
    Nicolet, Anna
    Al-Gobari, Muaamar
    Perraudin, Clemence
    Wagner, Joel
    Peytremann-Bridevaux, Isabelle
    Marti, Joachim
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [27] What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?
    Freemantle, Nick
    Calvert, Mel
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 1352 - 1354
  • [28] Proteomics Research to Discover Markers: What Can We Learn from Netflix®?
    Ransohoff, David F.
    CLINICAL CHEMISTRY, 2010, 56 (02) : 172 - 176
  • [29] Prostate cancer screening: what can we learn from randomised trials?
    Auvinen, Anssi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (01) : 12 - 17
  • [30] Blockchain Governance: What We Can Learn from the Economics of Corporate Governance
    Allen, Darcy W. E.
    Berg, Chris
    JOURNAL OF THE BRITISH BLOCKCHAIN ASSOCIATION, 2020, 3 (01) : 46 - 52